Search Results
Jul 29, 2026, 10:31 ET Graves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsight
Graves ophthalmopathy market in the coming years. The promising Graves ophthalmopathy therapies in clinical trials include Elegrobart (VRDN-003), Linsitinib, AMG 732, Lonigutamab, ENSPRYNG (satralizumab, RG6168), and others.Discover which companies are leading innovation or
More news about: DelveInsight Business Research, LLP
Nov 06, 2025, 11:05 ET 再鼎醫藥公布 2025年第三季度財務業績和近期公司進展
研究進行中期分析。Vertex預計在2025年底前向FDA提交用於IgA腎病治療的BLA的首個模塊，並計劃於2026年上半年完成BLA提交，以期在美國獲得加速批准。 VRDN-003 （胰島素樣生長因子 1 受體抑制劑 , 皮下注射）
More news about: 再鼎醫藥
Oct 02, 2025, 17:31 ET Graves' Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the Forecast Period (2025-2034) | DelveInsight
antibody developed for multiple IgG-mediated autoimmune disorders. IGF-1R inhibitors, including Veligrotug (VRDN-001) and VRDN-003, decrease proptosis and orbital inflammation, with VRDN-003 providing an extended half-life and flexible dosing. Collectively, these therapies offer complementary, targeted
More news about: DelveInsight Business Research, LLP